Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom. Shares ...

Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Pharmaceutical titan Eli Lilly has delivered a quarterly report that dramatically surpassed market forecasts, sending waves ...

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

This proprietary system employs specialized algorithms to identify early signs of litigation trends in federal litigation filings. Click here to learn more about Law.com Radar's new suit alerting and ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, has announced an unsolicited bid to ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

NEW YORK (AP) — The U.S. stock market sank from its record heights on Thursday, as Wall Street sifted through mixed ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...